Skip to main content
Premium Trial:

Request an Annual Quote

Structural Genomics Consortium to Use RoboDesign s Protein Crystallization Platform

NEW YORK, April 6 (GenomeWeb News) - Laboratory automation firm RoboDesign International said today that the Structural Genomics Consortium has selected its CrystalMation protein crystal imaging and analysis technology as its standard protein crystallography platform.

The SGC is a not-for-profit organization funded by the Wellcome Trust, GlaxoSmithKline, Genome Canada, the Ontario Research and Development Challenge Fund, the Ontario Innovation Trust, and the Canadian Institutes of Health Research. The initiative was launched in April 2003 with the goal of developing the infrastructure and technologies necessary to determine 200 protein structures per year. The SGC said it will target 350 medically significant proteins over the first four years.

The SGC will use the Minstrel III and RoboIncubator combinations of the CrystalMation platform in its high-throughput crystallography facility at the University of Oxford. RoboDesign said that it would deliver the systems this May.

Financial terms of the agreement were not provided.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.